Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

The company holds several patents for the composition and use of BCG combined with Anktiva in bladder cancer treatment. The rBCG vaccine, originally developed as a live vaccine against ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for ... combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent ... potential benefits to patients, potential treatment outcomes for patients, the described ...

Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies ...

The alternative BCG source has been developed by the Serum Institute of India, the world’s largest manufacturer of vaccines by volume. In bladder cancer clinical trials in Europe, the ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation ... (other than Bacillus Calmette-Guérin [BCG]) or radiotherapy to the bladder. Patients were either ...

The alternative BCG source has been developed by the Serum Institute of India, the world’s largest manufacturer of vaccines by volume. In bladder cancer clinical trials in Europe, the ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent ... potential benefits to patients, potential treatment outcomes for patients, the described ...